Insights
At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.
Reflections on The Initial Impact of COVID-19 on Global Market Access Activities
Inbeeo dives into the data from our COVID-19 Impact on Market Access Activities Dashboard and identifies three positive trends that emerged.
How Payers in the US & Europe are adapting to the ATMP revolution
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
Drug R&D Public Funding – The Next Level Of Price Transparency Policies?
French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.
Tackling Rising Drug Costs in the US: Is ERP an Option?
Rising drug prices in the US are hot topic. Inbeeo takes a look at the recent drug pricing proposal by the Democrats suggesting the use of ERP.
4 Take-Away Messages From The Zolgensma® Pricing Storm
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
Decoding the data: Analytics of Drug Pricing Tweets
Inbeeo's analysis of 2018 drug pricing tweets using NLP machine learning techniques highlight how emotive the issue of pharmaceutical pricing really is.
Four Definitions of Value-Based Pricing and Counting
What is Value-Based Pricing? It's pricing based on value! Or is it? Let us try to define what it is once and for all.
In France, the value equation may change (a little)
France's healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.
Six Drugs that Cost a Medicare Part D Beneficiary more than $10,000 a Year
No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s - offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.
The Dust Never Settled after Drug Pricing 9/22
The event that made people pay attention to how prescription drugs are being priced
Why I Prefer a Value-Based Healthcare Mayhem over the Status Quo
The value-denial syndrome used to be broadly shared between payers and the industry, and now they both seem to come to the same realization that value-based pricing is the only way. Easier said than done, but that's a start.
Healthcare Appraisal: The Evolution of Value Based Healthcare
The Health Foundation and ICHOM are among the many stakeholders calling for an evolution of how we look at value in healthcare. Here are four trends emerging from their pledge.
Ask Not What Payers Can Do for You – Ask What You Can Do for Payers
Five tips worth keeping mind when planning for market access. An infographic.
Three Reasons Why Value Definition Is The Ultimate Challenge for Pharma
I have learned the hard way that defining the value of a pharmaceutical innovation is not as easy as "Bob's your uncle".
Care Affordability Index or How to Go Beyond the “# of Lives Covered” Metric
A Care Affordability Index could constitute a way more informative measure of patient-access performance than the binary “number of lives covered”. And it is not that complicated to implement. A post for dashboard lovers.
All articles loaded
No more articles to load
